© 2021 AlphaMed Press.Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients with cancer show worse outcomes compared with patients without cancer. The humoral immune response (HIR) of patients with cancer against SARS-CoV-2 is not well characterized. To better understand it, we conducted a serological study of hospitalized patients with cancer infected with SARS-CoV-2. Materials and methods: This was a unicentric, retrospective study enrolling adult patients with SARS-CoV-2 admitted to a central hospital from March 15 to June 17, 2020, whose serum samples were quantified for anti-SARS-CoV-2 receptor-binding domain or spike protein IgM, IgG, and IgA antibodies. The aims of the study were to assess the ...
BACKGROUND: Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVI...
Abstract: Background: Coronavirus disease (COVID-19) is interfering heavily with the screening, diag...
Background Patients with solid or hematological tumors or neurological and immune-inflammatory disor...
Little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individ...
: Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following...
Funder: National Institute for Health Research; funder-id: http://dx.doi.org/10.13039/501100000272Ba...
Background: Systemic immunosuppression characterizing cancer patients represents a concern regarding...
Patients with cancer are at high risk for severe COVID-19 diseases and show impaired immune response...
BACKGROUND Progress in characterising the humoral immune response to Severe Acute Respiratory Syn...
Background Progress in characterising the humoral immune response to Severe Acute Respiratory Syndro...
Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited....
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the ...
Introduction Progress in characterising the humoral immune response to Severe Acute Respiratory Synd...
Background: Protective and lasting immunity to viral infections or vaccines are usually achieved thr...
Background Patients with solid or hematological tumors or neurological and immune-inflammatory disor...
BACKGROUND: Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVI...
Abstract: Background: Coronavirus disease (COVID-19) is interfering heavily with the screening, diag...
Background Patients with solid or hematological tumors or neurological and immune-inflammatory disor...
Little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individ...
: Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following...
Funder: National Institute for Health Research; funder-id: http://dx.doi.org/10.13039/501100000272Ba...
Background: Systemic immunosuppression characterizing cancer patients represents a concern regarding...
Patients with cancer are at high risk for severe COVID-19 diseases and show impaired immune response...
BACKGROUND Progress in characterising the humoral immune response to Severe Acute Respiratory Syn...
Background Progress in characterising the humoral immune response to Severe Acute Respiratory Syndro...
Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited....
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the ...
Introduction Progress in characterising the humoral immune response to Severe Acute Respiratory Synd...
Background: Protective and lasting immunity to viral infections or vaccines are usually achieved thr...
Background Patients with solid or hematological tumors or neurological and immune-inflammatory disor...
BACKGROUND: Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVI...
Abstract: Background: Coronavirus disease (COVID-19) is interfering heavily with the screening, diag...
Background Patients with solid or hematological tumors or neurological and immune-inflammatory disor...